

Exploring the complexities of drug formulation selection, storage, and shelf-life for exploration spaceflight

Vernie R. Daniels ¹, Edward S. Williams ²

¹ KBR, Houston, TX, 77058, USA

² NASA Johnson Space Center, Houston, TX 77058, USA

Introduction

Medications have been a part of space travel dating back as far as the Apollo missions. Currently, medical kits aboard the ISS contain medications and supplies to help crew members cope with a variety of possible medical events. NASA reported that 1,867 medical events occurred from 1981 to 1998 on space shuttle flights, STS-1 to STS-89; 498 out of the 508 crewmembers on those flights reported experiencing a medical event other than space motion sickness ¹. In 2000, the Institute of Medicine (IOM) convened a committee of experts, Committee on Creating a Vision for Space Medicine during Travel beyond Earth Orbit, to examine the issues surrounding astronaut health and safety for long duration space missions. The primary theme of the committee's final report is that there is not enough known about the risks to human health during long-duration missions beyond Earth's orbit and ways to effectively mitigate those risks in an environment of deep space ². In 2014, the IOM convened the Committee on Ethics Principles and Guidelines for Health Standards for Long Duration and Exploration Spaceflights and released a report emphasizing the importance of prevention, mitigation, and treatment of major risks to human health during exploration spaceflight ³. NASA's Human Research Program has organized five distinct categories of spaceflight hazards summarized by the acronym "RIDGE" (Space **R**adiation, **I**solation and **C**onfinement, **D**istance from Earth, **G**ravity fields, and **H**ostile/**C**losed **E**nvironments) that astronauts may encounter during exploration spaceflight ^{4,5}. From those hazards, NASA further derived 30 of the most critical human health and performance risks, including limits to medical care resulting from pharmaceutical degradation ⁶. As we prepare for more distant exploration missions to Mars and beyond, risk management planning for astronaut healthcare should include the assembly of a medication formulary that is comprehensive enough to prevent or treat anticipated medical events, remains safe and chemically stable, and retains sufficient potency to last for the duration of the mission. The present editorial will summarize the current state of knowledge regarding innovative formulary optimization strategies, pharmaceutical stability assessment techniques, and storage and packaging solutions that could enhance drug safety and efficacy for future exploration spaceflight missions.

Pharmaceutical Formulary Optimization

A safe and effective medication formulary is essential to maintaining crew health and performance during long-duration spaceflight outside of low-Earth orbit (LEO). Distance from Earth creates four key operational changes that increase medical risks, including communication, consumables resupply, crewmember health, and evacuation ⁷. The spaceflight pharmaceutical formulary consists of medications indicated to treat a variety of anticipated medical events and healthcare needs during spaceflight. The specific medications in the formulary may change to optimally align with the mission, crew

compliment, and spacecraft design. Currently, medical support missions at low Earth orbit (LEO) depend on a robust consumables resupply chain, which will be strained for lunar and possibly non-existent for a Mars mission ⁷⁻¹¹. Long-duration exploration missions will differ from missions in LEO due to mission duration, lack of consumables resupply, prolonged exposure to space radiation, and the absence of emergency medical return capability. Increased distance and mission length are expected to increase medical and total mission risk. Loss of medication resupply limits or removes the ability to replace medications that have been exhausted or degraded, potentially exacerbating the medical risk posture. To address these anticipated risks, long-duration missions must consider use of new medical technologies, treatment modalities, and smarter medical systems that offer greater crew autonomy ¹².

Personalized medicine refers to an approach to patients that considers their genetic composition but with attention to their preferences, beliefs, attitudes, knowledge, and social context; whereas, precision medicine describes a model for health care delivery designed to optimize efficiency or therapeutic benefit for a particular patient or group of patients and relies heavily on data, analytics, and information^{6,10}. NASA and other Space Agencies have started to investigate the benefits of genomics and precision medicine to obtain the scientific evidence needed to understand how humans adapt to and function in the unique environment of space ⁶. In 2015, the European Space Agency (ESA) published the results of a pharmacogenomics assessment of the International Space Station (ISS) pharmaceutical formulary. The ESA results revealed a 30% user-specific variance in metabolism, strongly suggesting the need for pharmacogenomic matching for a future exploration spaceflight formulary ¹³.

The NASA Lifetime Surveillance of Astronaut Health (LSAH) proactively collects data on astronaut medical care and workplace exposures, especially those occurring in the training and spaceflight environments, and conducts operational and health care analyses to look for trends in exposure and health outcomes. NASA's Life Sciences Data Archive also includes data from human subjects derived from both past and current spaceflights, as well as data from analog studies to form a more comprehensive reference database for analysis. The Integrated Medical Model (IMM) is a Probabilistic Risk Assessment (PRA) Monte-Carlo simulation tool developed by NASA to inform ISS and other PRA based mission analyses ^{7, 11, 13}. The IMM was developed at NASA starting in 2008 and was transitioned to operations in 2017 ¹⁴. The IMM models 100 medical conditions and includes the capability to assess the impact of resource limitation or depletion on successful treatment of medical conditions by incorporating evidence from all ISS missions as well as data from Apollo, Skylab, Mir, and Space Shuttle programs, thereby providing valuable information for mission planners ¹⁰. Correlating LSAH data with supportive IMM incidence data suggests that medications could treat or mitigate many of the medical events experienced by NASA astronauts during previous space missions.

H. Nguyen et al. incorporated the prediction capability of physiologically based pharmacokinetic (PBPK) models into a rational drug degradation risk assessment procedure using a series of model drug degradants (substituted anilines). The PBPK

models are parameterized using a combination of experimental and literature data and computational methods. The impact of model parameter uncertainty is incorporated into a risk assessment procedure based on the novel use of a statistical metric called “PROB” for comparing the probability that a human toxicity-target tissue exposure exceeds the rat exposure level at a critical no-observed-adverse-effect level. When compared with traditional risk assessment calculations, this novel PBPK approach appears to provide a rational basis for drug instability risk assessment by focusing on target tissue exposure and leveraging physiological, biochemical, and biophysical knowledge of compounds and species¹⁵. Deepika and Kumar summarized recent developments in building quantitative adverse outcome pathways (qAOPs) for several endpoints such as developmental neurotoxicity (DNT), hepatotoxicity, and cardiotoxicity, and how usage of machine learning and artificial intelligence may improve and advance the existing PBPK framework¹⁶.

An increasing number of pharmaceutical and medical device companies are introducing innovations such as nanobots, implants, artificial intelligence (AI), and wearable drug delivery/monitoring devices. AI and Machine Learning (ML) algorithms have slowly but surely begun to revolutionize pharmaceutical industry and drug development in recent years. In 2019, Koromina et al. illustrated how AI, encompassing ML, and other approaches such as deep learning could be implemented in clinical practice towards the improvement of precision medicine and drug discovery. AI and computational algorithms can be harnessed with pharmacogenomics expertise to better guide drug discovery and development pipelines¹⁷.

There are many success stories in the pharmaceutical industry using cell-based disease models to identify new indications or repurposing drugs already approved by the U.S. Food and Drug Administration (FDA)^{18,19}. Madrid and Chang proposed that drug repurposing using prior FDA approved drugs with well understood mechanisms of action, qualified chemistry, manufacturing protocols, and safety profiles offered an attractive strategy for delivering a new approach for developing new medical countermeasures (MCM) to protect humans from space radiation in long-term missions. For example, the biologic product Romiplostim (Nplate®) is currently approved to treat idiopathic thrombocytopenic purpura. Under a radiation medical countermeasure product development support program funded by National Institute of Allergy and Infectious Diseases, SRI conducted a series of animal studies to support Amgen’s FDA supplemental Biological License Application to repurpose Romiplostim as a medical countermeasure for hematopoietic acute radiation syndrome. Madrid and Chang are currently working on an NCI sponsored drug screening program targeting the Artemis endonuclease enzyme for radiotherapy using a miniaturized cellular V(D)J recombination assay with chromosomal substrates²⁰.

Manian et al. illustrated how multi-modal gene disease and disease drug networks, along with link prediction algorithms, were used to identify the main gene regulators responsible for skeletal muscle atrophy from spaceflight microgravity and the repurposed drug treatments with the highest probability of successfully managing the condition^{21, 22}. Harvested muscle tissue from mice exposed to spaceflight, made

available by the NASA GeneLab repository, was exposed to RNA and DNA sequencing to generate transcriptomic datasets. The datasets were then mined to identify key genes and muscle atrophy gene regulators were selected using the Bayesian Markov blanket method. A Gene Disease Knowledge Graph (GDKG) was constructed using a scalable precision medicine knowledge engine. A total of 21 drugs were identified as possible candidates for treating muscle atrophy. This innovative method of combining six GeneLab datasets with other disease and drug databases, followed by use of applied network analysis and artificial intelligence methods, offers promise for furthering drug repurposing efforts ²¹. In a follow-up publication, Manian et al. expanded their drug repurposing research by mining seven GeneLab datasets to identify the key genes and drugs associated with skeletal muscle atrophy. The key genes were recognized as those associated with metabolic and neurodegenerative diseases. The repurposed drug candidates targeted by the graph convolution network method were determined to be nutrients, corticosteroids, anti-inflammatory medications, and insulin related treatments. This work offers promise that these network analyses and ML methods can be utilized to generate disease drug networks that are scalable and applicable to multiple datasets, genes, and drugs, which could lead to the identification of repurposed drug candidates for multiple medical conditions ²².

Lu et al. recently developed a de novo design platform, SECSE, that integrates human intelligence for systemic evolutionary chemical space exploration against a specific protein pocket. The platform incorporated design rules of medicinal chemistry, computational evaluation methods, and deep learning models to efficiently speed up the search process of virtual hit compounds. Application of SECSE against phosphoglycerate dehydrogenase (PHGDH) proved its potential in finding diverse, potent, and novel drug-like chemotypes that are attractive starting points for further validation ²³.

Seoane-Viano et al. summarized several promising therapeutics for anticipated clinical condition management, emerging technologies focused on pharmaceutical manufacturing (e.g., Chemputing, synthetic biology, and 3D printing), and storage; management in space; and recommendations to facilitate adoption, regulatory oversight, and enforcement ²⁴⁻²⁹. Chemputing represents a novel method of synthesizing drug molecules using a modular chemical-robot system known as a Chemputer ²⁶. Scientists at the University of Glasgow were able to successfully synthesize medications including rufinamide, diphenhydramine hydrochloride, and sildenafil. They also developed the Chempiler, which automated synthesis performed by the Chemputer, thereby generating higher output yields than those achieved manually. The Defense Advanced Research Projects Agency's (DARPA) Pharmacy on Demand (PoD), and the Biologically derived Medicines on Demand (Bio-MOD) programs focus on manufacturing therapeutic products on-demand ²⁵. The PoD has successfully developed four medications (diphenhydramine hydrochloride, lidocaine hydrochloride, diazepam, fluoxetine hydrochloride) synthesized from raw materials. The Bio-MOD system was designed to generate therapeutic proteins in small doses at the point-of-care within 24 hours ³⁰. Synthetic biology is an emerging discipline aiming to reengineer microorganisms to manufacture biological, protein-based drug products ^{31, 32}.

NASA's Translational Research Institute for Space Health (TRISH) has funded a project at the Massachusetts Institute of Technology (MIT) to develop a gastric resident device for in-situ production of drugs, called the "mother machine", which uses bacterium to produce and release melatonin, caffeine, and acetaminophen within the stomach after ingestion ²⁴. In another TRISH-funded project, researchers at the University of California Davis are developing plant-based methods to produce protein-based pharmaceuticals in under 24 hours for use in deep space missions ³⁵. The researchers chose lettuce as their host plant as it had already been successfully grown on the ISS. Lettuces were infected with *Agrobacterium tumefaciens* containing a DNA sequence encoding the desired protein, which is subsequently transcribed and translated into the functional protein. They focused on producing three therapeutic proteins (a parathyroid hormone for bone loss, a granulocyte colony-stimulating factor for radiation sickness, an anti-fungal peptide) ³⁶. The use of probiotics and prebiotics as food additives or supplements were presented as promising countermeasures of microbiome dysregulation to benefit overall gut health during spaceflight ³⁷. Synthesis of a combination of melanin with selenium, selenomelanin, has demonstrated the ability to absorb X-rays more efficiently than melanin alone ³⁸. Westover et al. conducted a study of the tardigrade, an invertebrate species sent into space by ESA, which was shown to survive up to 5kGy of ionizing radiation and the vacuum of space. This study revealed a unique damage suppressor protein that protects the organism from exposure to ionizing radiation free radicals. The protective effect of this protein could potentially be used to mitigate oxidative stress damage resulting from chronic exposure to space radiation ³⁹.

Simon et al. explored repurposing therapeutics with bactericidal activity to tackle concerns with multiple drug resistance (MDR). Phenothiazines, as efflux pump inhibitors, may be able to augment the antimicrobial activity of antibacterial agents and increase their intracellular concentration. Although clinical use of most phenothiazines is prohibitive due to clinical and cellular toxicity, their prospective antimicrobial properties offer promise for tackling MDR. Simon et al. conducted stability studies on phenothiazines pre- and post-hypergravity exposure, examining their multifunctionality and ability to transform into antimicrobial agents in response to laser irradiation. PMZ exposure to Ultraviolet-visible (UV-Vis) absorption spectrum in dark and ambient light environments resulted in slowed degradation in the dark environment and changes in the absorption spectra in response to generation of the more polar photodegradation products. Other promising compounds reviewed included the organoselenium compound Ebselen (5-fluoro-2'-deoxyuridine), demonstrating in-vitro and in-vivo antimicrobial activity against *Staphylococcus aureus*, diazabicyclooctane (DBC) a β -lactamase inhibitor, quinazoline derivatives, imidazolidine-4-ones to boost the effectiveness of antibiotics against *S. aureus*, and the synergistic increase in antimicrobial activity generated by combining the anti-diarrheal loperamide with tetracyclines ⁴⁰⁻⁴¹.

Pharmaceutical Stability and Shelf Life

Once the ideal formulary for exploration space is determined, it is essential to establish the chemical and physical stability of each medication compound, as well as its safety by identifying its degradation profiles and products. Therapeutic effectiveness and safety of pharmaceuticals are critical to the success of exploration spaceflight. Although few studies have been conducted to provide evidence on the physicochemical stability of pharmaceuticals during space missions, the data suggests that the spaceflight environment may promote degradation in some pharmaceuticals^{9, 10, 42-50}. Changes in active pharmaceutical ingredient (API) concentration or drug dosage form release could lead to inefficacy, treatment failure, or pharmacological toxicity. The United States Pharmacopeia (USP) defines potency, quality, safety, and stability acceptance criteria for finished pharmaceutical products (FPPs) approved by the FDA. Pharmaceutical stability studies are required by the FDA to demonstrate that a pharmaceutical product meets its acceptance criteria or remains within established limits of quality, potency, and purity throughout a specified time of storage⁴³. Conducting stability studies help characterize how the API or FPP varies with time under the influence of environmental factors such as temperature, humidity, and radiation^{43-44, 51-52}. A drug product's shelf life or expiration dating period is defined as the time that a drug product is expected to remain potent within approved specifications, while stored under the conditions defined by the manufacturer on the container label⁵¹⁻⁵². Many factors contribute to the chemical and physical stability of an FPP, including composition of the API, interactions between the API and excipients or inactive ingredients, environmental conditions during shipment, storage and handling, and the product's shelf life. The chemical stability of an FPP can be influenced by environmental factors such as heat, radiation, moisture, and chemical factors such as pH, oxidation, reduction, hydrolysis, or photodegradation reactions^{43, 53 - 54}. An FPP's physical stability can be impacted by attributes such as solid dosage form hardness, brittleness, or particle size, which could compromise API solubility, dissolution, or API release from the FPP^{43, 53}. Pharmaceutical excipients are also important components to FPP stability. Excipients serve as diluents, fillers, binders, disintegrants, lubricants, coloring agents, and preservatives in FPPs. Although the ideal excipient is incorporated into the FPP to enhance manufacture, administration, or product stability, some can initiate, propagate, or participate in chemical or physical interactions with the API, leading to compromised drug safety and effectiveness^{54 - 55}.

Pharmaceutical stability testing conducted under Good Manufacturing Practices (GMP), primarily utilizes the stability-indicating assay and impurities method, a gradient reversed-phase liquid chromatography method such as High-performance Liquid Chromatography (HPLC), or Gas Chromatography (GC), coupled with spectrometry detection capable of separating product APIs, impurities, and degradation products (e.g., Mass Spectrometry (MS), Ultraviolet (UV), Raman, Infra-red (IR), Nuclear Magnetic Resonance (NMR))⁴³. Results obtained from these stability-indicating assays are used by pharmaceutical manufacturers to support the establishment of expiration dates for regulatory filings⁵⁶.

Chromatographic techniques require destruction of the drug sample by extraction of the API in organic solvent mixtures and water. Spectroscopy provides fast and nondestructive analyses with high chemical specificity for the determination of drug quality parameters⁵⁷. Spectroscopy is used throughout pharmaceutical production to confirm levels of APIs and impurities. Several spectroscopic techniques such as Raman (using visible light), IR, Near-Infrared (NIR) (using IR or near-IR radiation), combined with chromatographic methods, statistical regression tools, and chemometric tools are now proposed for pharmaceutical quality assessments⁵⁸⁻⁶⁰. Raman spectroscopy can not only support non-destructive quality testing of drug substances, it can also support routine safety and quality screenings of FPPs⁶¹. Although IR spectroscopy had been the spectroscopic method of choice for identification and quantification of pharmaceutical products under standardized conditions, the European Pharmacopoeia (Ph. Eur.) presented the first general chapter for Raman spectroscopy in 2002, with revisions in 2016 and 2021 to include hand-held Raman spectrometers, and their use as process analytical technology (PAT). Likewise in 2016, and in harmonization with the Ph. Eur., the USP replaced former Raman Chapter <1120>, with Chapters <858> and <1858>, made further revisions in 2020—2022, and created a new Chemometrics chapter <1039>⁶¹⁻⁶².

K. Shah et al. reviewed recent advancements and applications for Raman spectroscopy in pharmaceutical analysis⁵⁷. K. Berzins et al. conducted a proof-of-principle study demonstrating a new Raman subtechnique from micro-spatially offset using low frequency Raman spectroscopy (micro-SOLFRS) to nondestructively obtain information about pharmaceutical solid dosage forms and surface-driven changes from exposure to environmental conditions (e.g., temperature, relative humidity)⁶³. Makki et al. applied Raman and IR spectroscopy for qualitative and quantitative analysis of commercially available therapeutic solutions of anti-cancer drugs (e.g., doxorubicin, epirubicin, daunorubicin), demonstrating that IR and Raman spectroscopy could support quality control of personalized chemotherapeutic solutions prepared for patients⁶⁴. M. Sultan et al. reported the application of Surface Enhanced Raman Scattering (SERS) for the rapid and cost-effective detection of warfarin in pharmaceutical dosage forms and plasma samples. The results were found to be highly precise and unaffected by the presence of excipients in the dosage forms⁶⁵. A novel approach to determining multiple analytes separately and simultaneously has been achieved using SERS substrate. In 2020, C. Liu et al. studied the use of ZnO/Ag substrate for rapid and non-invasive determination of two oral antidiabetic drugs, pioglitazone and phenformin⁶⁶. E.M. da Silva et al. used Raman spectroscopy for the determination of amlodipine besylate and hydrochlorothiazide using a composite of graphite and polycaprolactone polymer in the analysis of tablets and urine samples⁶⁷. Z. Wang et al. compared the effectiveness of Raman spectroscopy with that of terahertz spectroscopy for the determination of enantiomers of ibuprofen. The results revealed higher accuracy (up to 97.04%) for the detection of (R)-(-)-ibuprofen and (S)-(+)-ibuprofen by terahertz spectroscopy compared to that of 52.89% for Raman spectroscopy⁶⁸. J. Zini et al. worked on the determination of metronidazole and vitamin C in anionic nanofibrillated cellulose hydrogels⁶⁹. G. Sarp and Yilmiz used Raman spectroscopy along with other advanced techniques for

characterization of multifunctional hybrid material g-C 3 N 4 @TiO 2 @Fe3O4 obtained by the degradation from trimethoprim and isoniazid ⁷⁰.

Confocal Raman microscopy (CRM) is an alternative analytical tool to investigate API stability and quality control utilizing two-dimensional sample characterization. Recent applications of Raman mapping on pharmaceutical formulations include the composition of tablets and the connection between composition and dissolution rate ⁷¹⁻⁷⁶. S. Fateixa et al. utilized Raman imaging methods to characterize the main components of commercial acetaminophen (APAP) tablets and the hydrolytic degradation product, 4-aminophenol (4-AP). This research demonstrated that the degradation product 4-AP in APAP tablets could be detected as low as 0.05 % w/w using Raman images ⁷¹. A satellite laboratory “toolkit” consisting of a handheld Raman spectrometer, portable direct analysis in real-time mass spectrometer (DART-MS), and portable Fourier transform infrared (FT-IR) spectrometer, was employed to examine 926 pharmaceutical products collected at an international mail facility for the presence of declared and undeclared APIs. In 68 days, the toolkit successfully identified over 650 APIs, using two or three devices. Comparative analysis conducted by a full-service analytical laboratory confirmed that 90.2% of the identified APIs, with no false positives, could be accurately detected by use of a minimum of two toolkit devices ⁷⁷.

Conducting stability testing is rigorous, expensive, and time-consuming, thereby warranting consideration of alternative methodologies that may offer statistically accurate estimations. In 2003, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) developed a systematic approach to drug design and testing known as “Quality-by-design” (QbD), which uses predefined objectives, science, and risk-based management approaches to gain product and process understanding. Quantile regression, or mixed model tolerance interval methods with similar approaches, analyze the observed data from sampled batches and model a quantile of the distribution of true batch shelf lives. These and other statistical modeling techniques may prove to be useful tools for predicting drug shelf life ⁷⁷⁻⁷⁹.

Accelerated Predictive Stability (APS) is considered a useful tool for defining and predicting the drug development life cycle, kinetic degradation, packaging selection, API retesting, and products of degradation, as well as understanding formulations ⁸⁰. APS has gained popularity, mainly to set expiry for clinical materials, has been accepted by multiple regulatory agencies, and is currently being investigated for stability prediction of biological products and extrapolation of dissolution slowdown of solid dosage forms ^{56, 80-83}. APS approaches, such as the Accelerated Stability Assessment Program (ASAP) and Accelerated Stability Modeling (ASM), are emerging approaches for performing Risk-Based Predictive Stability (RBPS) assessments. ASAP uses a moisture modified Arrhenius approximation, employing degradation kinetics at a few stressed conditions during 1–2 weeks, and extrapolates to lower temperatures and humidity for longer timeframes ^{81, 82}. The advantages of this strategy are the shorter experimental timelines and the fewer resources required. The accuracy of this model assumes a first-order reaction, typical of hydrolysis-based degradation ⁵⁶. APS studies, carried out over a 3–

4-week period and combining extreme temperatures and relative humidity (RH) conditions (40–90 °C)/10–90% RH, have emerged as novel approaches to predict the long-term stability of pharmaceutical products in a more efficient and less time-consuming manner ⁸³.

C. Merienne et al. estimated the shelf-life of two formulations of amoxicillin using a semi-predictive methodology. The characterization of amoxicillin-MCC mixture was assessed by attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-FTIR). The content profiles were determined by a stability indicating chromatographic method and fitted to pre-defined kinetic models performed by APS. A rationalization of formulation was elaborated by considering molecular structures, vibrational spectrometry analysis of amoxicillin dosage forms, the HPLC-UV quantification of amoxicillin degradation products, and the fit of experimental data to degradation models enabling to predict the shelf-life of amoxicillin dosage forms in a lean approach of storage conditions ⁸⁴.

Furness et al. proposed Modeling Approaches to Reimagine Stability (MARS) to support establishment of tentative drug substance retest periods and/or shelf-life of the FFP. MARS refer to using stability data collected over a much shorter time span of 3–6 weeks at elevated temperature and humidity beyond conventional ICH Q1A (R2) stability protocols. Data mining of Investigational New Drug (IND), New Drug and Abbreviated New Drug Applications (NDA, ANDA) that used “Accelerated Stability Assessment” or other MARS tools (e.g., ASAP, ASM, APS, RBPS) yielded 172 results, from 2007–2021, including 121 IND, 39 NDA, and 12 ANDA. An underlying assumption of MARS is that there are no physical changes such as API melting or polymorph interconversions. The results illustrated that MARS data can provide an important bridge between the supportive stability data and the limited primary stability data to enable establishing a tentative retest/expiration dating period ⁸⁵.

Pharmaceutical Packaging and Storage Considerations

Non-destructive pharmaceutical analysis and statistical modeling techniques could optimize exploration spaceflight medical care by enabling early detection of suboptimal therapeutics. Likewise, novel packaging, storage strategies, and dosage form innovations are promising countermeasures to enhance drug stability and shelf-life of exploration spaceflight medications ⁴⁰⁻⁴⁴. P. Mandal et al.⁸⁶ reviewed recent pharmaceutical packaging strategies aimed at controlling humidity and oxygen levels. Presented strategies included desiccant film technology developed as active-blister packaging to protect oral solid dosage forms from hydrolytic degradation, incorporation of antioxidants, specialized coatings applied to the API, use of oxygen scavengers, and use of modified atmosphere packaging materials.

Jafarzadeh et al.⁸⁷ reviewed the utility of biopolymer films with synthesized nanomaterials. The reviewed research demonstrates the unique characteristics of nanomaterials, particularly their high surface area, making them ideal for higher process efficiency. This review also presents nanocomposite films as the next generation UV-blocking composite material that could be improve pharmaceutical packaging and

storage. Presented packaging enhancements included the development of a gellan gum-TiO₂ nanotubes-based bio-nanocomposite film added to a gellan gum/xanthan gum nanocomposite by Rukmanikrishnan et al.⁸⁸ This combination provides increased thermal stability, tensile strength, and decreased the water vapor permeability of the nanocomposite films, ideal for food and pharmaceutical packaging⁸⁸. The review also included a study by Patil et al.⁸⁹ who developed a highly flexible, transparent, and re-emissive composite film from polyvinyl alcohol (PVA) and tea waste-derived (WTR) Carbon quantum dots (CDs). They found that the higher the concentration of WTR-CDs in PVA films, the higher the ultraviolet (UV) blocking ability of the composite films (100% of UV-C, 100% of UV-B, 20–60% of UV-A region). These observations demonstrate that composite film could be the next generation UV-blocking composite materials for pharmaceutical storage. Razali et al.⁹⁰ developed gellan gum-TiO₂ nanotubes-based bio-nanocomposite film with high TS, Young modulus, and antibacterial activity against *Streptococcus*, *E. coli*, *Pseudomonas aeruginosa*, and *S. aureus*. Similarly, zinc oxide NPs were added to the gellan gum/xanthan gum nanocomposite, increased the glass transition temperature, thermal stability, and TS and decreased the WVP of the nanocomposite films, which can be used in food and pharmaceutical packaging⁸⁸. Incorporating kaolin into thermoplastic starch led to an around 130% and 50% increase in the TS and elastic modulus of the film, respectively. In addition, kaolin resulted in a significant decrease in moisture uptake in comparison with the pure starch matrix. It has been reported that the mechanical and physical properties of conventional composites or pure polymer can be remarkably improved by the nanometer-size dispersion of polymer–clay nanocomposites⁹¹. There have been similar results reported by Tang et al.⁹²

Since compacted lunar soil samples have shown shielding qualities against space radiation, Chakravarti et al.⁹³ proposed constructing a barrier from lunar soil as protective pharmaceutical storage on the Moon and to consider Martian soil for comparable storage on Mars. Several materials (e.g., polyethylene, boron, water, and tungsten) were also discussed for their abilities to effectively absorb primary radiation, thereby eliminating the generation of secondary radiation. Boron carbide composites were highlighted as lighter than traditional aluminum shields with better tensile qualities than high-density polyethylene.

Seoane-viano et al.²⁴ reviewed packaging materials that could help prevent radiation-induced degradation of drugs. Low atomic number and hydrogenous materials (e.g., polyethylene) were found to be more effective than high atomic number materials (e.g., aluminum), at reducing space radiation exposure. Two reviewed studies (Iguichi et al.⁹⁴ and Naito et al.⁹⁵) proposed that novel hydrogen-rich materials with better radiation shielding capabilities could help protect drugs from space radiation on future space missions.

J. Vieregg et al.⁹⁶ studied the hybrid packaging material known as SioPlas™, consisting of an ultrathin multilayer ceramic coating applied to the interior of cyclic olefin polymer (COP) plastic container with a plasma-enhanced chemical vapor deposition. The novel coating process decreases oxygen permeation through the vial wall 33-fold, as

compared to uncoated COP containers. Two biologic drug products, exposed to gamma and electron beam sterilization and stored in SioPlas™ vials, revealed lower levels of oxidation as compared to matching control and irradiated products stored in glass vials.

According to Mehta and Bhayani ⁴³, pharmaceutical shelf-life can be influenced by dosage form, excipients, and packaging material. Suggested strategies to stabilize pharmaceuticals in space included use of radiation attenuating container/closures and packaging materials constructed of polymeric materials with low atomic number (e.g., high density polyethylene), which can be further enhanced by incorporating boron or tungsten fillers.⁹⁷ The importance of FFP excipient selection was also highlighted with emphasis on radioprotective excipients (e.g., mannitol, nicotinamide, and pyridoxine) shown to prevent degradation during radiosterilization ¹⁰⁰. The use of novel dosage forms (e.g., micro/nanoformulations) has demonstrated radioprotection against ionizing radiation ⁹⁸⁻⁹⁹.

Ionizing radiation (IR) poses a growing threat to human health; thus ideal radioprotectors with high efficacy and low toxicity still receive widespread attention in radiation medicine. Despite significant progress made in conventional radioprotectants, high toxicity, and low bioavailability still discourage their application. Nano-radioprotectants are characterized by high efficacy, low toxicity, prolonged blood retention, and are equipped with enhanced bioavailability, improved stability, and increased solubility. Guo et al.¹⁰¹ reviewed recent advances in nanocrystallization of traditional radioprotectants, which involves the polymerization (e.g., emulsification, high-pressure homogenization) of radioprotective agents into nanoparticles, improving solubility, efficacy, and bioavailability ¹⁰²⁻¹⁰³. Currently nanotechnology-based preclinical studies are underway, as well as clinical trials evaluating nanotechnology-based delivery systems for the treatment of cutaneous melanoma¹⁰⁴.

Protection of moisture sensitive oral dosage forms is essential to product stability and quality. Drug hydrolytic degradation, caused by atmospheric moisture, significantly reduces the therapeutic effect of pharmaceutical solid dosage forms. Moisture barrier film coating is one of the most appropriate and effective approaches to protect the API from hydrolytic degradation during the drug manufacturing process and storage. Yang et al.¹⁰⁵ summarized recent advances in moisture barrier coatings and strategies to effectively decrease water vapor permeability and improve the moisture barrier function of film coating. Those strategies include newly designed coating formulations containing polymers with optimized functionality of moisture barrier and newly developed dry coating processes that eliminate the usage of organic solvent and water. Film-forming polymers include water-soluble, cationic, anionic, or neutral insoluble polymers from different chemical structures. Several new formulations comprising plant-based materials like zein and abietic acid have been designed and developed. Additionally, new and effective additives, such as suberin fatty acids (SFAs), have also been developed to improve the commonly used moisture barrier polymers such as hydroxypropyl methyl cellulose (HPMC).

Rolley et al.¹⁰⁶ spotlighted the development of an instrumented microfluidic pilot considered as a Galenic Lab-on-a-Chip to formulate nanomedicines. Benefits linked to the use of nanocarriers for delivery of drugs are a decreased degradation of active agents and a reduced toxicity. The concept of Quality by Design has attracted a growing interest in the development of new nanocarrier based dosage forms. This study demonstrates how additive manufacturing and microfabrication techniques can be used for the production of lipid nanocapsule nanomedicines.

Tablet coating is a process driven by technology, relying on advancements in coating techniques, equipment, coating materials, and quality assessment techniques. A. Salawi et al.¹⁰⁷ provided a review on film coating of solid dosage forms (e.g., tablets), with a focus on the polymers and processes used for tablet coating. Tablets susceptible to degradation through moisture or oxidation can be coated using a film-coating (FC) technique using biopolymers¹⁰⁸. APIs, which are sensitive to light, can be protected by coating with opacifying agents. Zein, a natural polymer derived from plant origin, is more beneficial than synthetic polymers. Because it is resistant to water, heat, and abrasion¹⁰⁹, products prepared using zein have improved shelf life. Active Film Coating (AFC) is a process of coating tablets or granules containing APIs using a solution or suspension. AFC can improve product stability, prevent interactions between APIs, and enable fixed dose combinations¹¹⁰⁻¹¹¹. FC is a critical but common process that enhances drug stability.

Highly hygroscopic pharmaceutical solid FPPs are prone to significant changes in their physicochemical properties due to chemical degradation and/or solid-state transition, resulting in adverse effects on their therapeutic performances and shelf life. L. Ng et al.¹¹² recommends four physiochemical stabilization strategies consisting of film coating (to form a thin film acting as moisture-barrier around the solid core containing the active ingredients); encapsulation (to envelop the active ingredients with polymers via spray-drying/freezing drying or complex coacervation), co-processing with excipients (to formulate the active ingredients with hydrophobic excipients to divert water away), and crystal engineering (to transform the crystalline form of the active ingredient to less-hygroscopic crystal forms). For hygroscopic pharmaceuticals, film coating and co-crystallization are the most common stabilization strategies. Film coating and encapsulation work by acting as barriers between the hygroscopic active ingredients in the core and the environment, whereas co-processing with excipients works mainly by adding excipients that deflect moisture away from the active ingredients. Most film-forming polymers for moisture-barriers are synthetic polymers, classified as water-soluble (e.g., polyvinyl alcohol, hydroxypropyl methyl cellulose), water-insoluble (e.g., ethyl cellulose), or entero-soluble polymers (e.g., shellac, Eudragit®). Plasticizers and pigments also play important roles in film coatings. Multiple cited examples from the literature demonstrate hygroscopic stabilization, including Zheng et al. who used hydrophilic poly(vinylpyrrolidone)'s (PVP) to coat citric acid-containing effervescent tablets to overcome high hygroscopicity¹¹³.

Innovative galenic strategies are employed to overcome low solubility in pharmaceutical formulation design. A. Zarinwall et al.¹¹⁴ successfully validated mesoporous silica

aerogels as an amorphization carrier matrix for the poorly water-soluble drug ibuprofen. Spatial confinement of APIs inside the pores of the silica aerogel matrix has the ability to substantially hinder the transformation into the crystalline state and hence tremendously improve the long-term stability of an amorphous drug.

Most sustainable polymer alternatives cannot compete with traditional plastics as gas and moisture barriers, thereby warranting the need for innovative chemistries and processing technology to enhance their barrier properties. B. Trinh et al.¹¹⁵ compiled a comprehensive summary regarding improvements on gas and moisture barrier properties of sustainable polymer packaging. The summary highlights signature accomplishments on the effect of tuning the microstructure, surface energy, morphology, and self-assembly of polymers to gas and moisture barrier properties of films and coatings. Recent developments in multiphase and multicomponent system design and the impact of nanotechnology on sustainable packaging was emphasized. The three main categories of polymer films and coatings are enhanced barrier, active, and intelligent/smart packaging materials. Barrier packaging provides moisture, gas, protection during production, transportation, and storage. Active packaging provides functional attributes in addition to a barrier. The only biodegradable polymer that provides superior moisture and oxygen barrier properties is poly(glycolic acid) (PGA)¹¹⁶. The combination of multiple materials in the form of blends, multilayers, and nanocomposites are proven strategies to meet industrial barrier standards (e.g., beverage, food, cosmetics, pharmaceutical). To further enhance the moisture and oxygen barrier properties, the addition of micro and nanofillers into the barrier layers such as nanoclay, nanocellulose, graphene, and metal oxide may also be employed^{117, 118}. With the current interest in nanotechnology, nanocomposite materials have attracted substantial research interest for packaging films and coatings. Different modelling approaches have proven that barrier properties have significantly improved with high aspect ratio nanoparticles in polymer matrices¹¹⁹. Natural hydrophobic biopolymers, and proteins (e.g., zein, keratin), are used to improve the water vapor permeability of packaging films due to their hydrophobic structures^{120, 121}. Zein, extracted from corn, is known to be insoluble in water and contain a large amount of hydrophobic amino acid domains^{122, 123}. Fabra et al.¹²⁴ developed a multilayer structure which includes interlayers of zein nanofibers on PHBV films to enhance the water vapor barrier of the resulting films. Similarly, keratin, found in mammal hairs and bird feathers, is hydrophobic and insoluble in water^{125, 126}. Thus, keratin has been incorporated with other biopolymers to improve water vapor barrier properties of multicomponent systems¹²⁷.

Bioregenerative life support systems may be a way to close this risk gap by leveraging in situ resource utilization (ISRU) to perform pharmaceutical synthesis and purification. M. McNulty et al.¹²⁸ used the equivalent system mass (ESM) metric to evaluate pharmaceutical purification processing strategies for longer-duration space exploration missions. Monoclonal antibodies, representing a diverse therapeutic platform capable of treating multiple space-relevant disease states, were selected as the target products for this analysis. Six technologies (three biotic and three abiotic capture methods) were compared and scheduled to minimize ESM for each technology. Scenario analyses

were performed to consider a range of input stream compositions and pharmaceutical demand, followed by a comparison of the base case ESM scenarios of alternative mission configuration, equipment models, and technology reusability. Six Protein A-based capture step procedures were analyzed: three commercially available abiotic technologies (pre-packed chromatography (CHM), spin column (SPN), and magnetic bead (MAG)) and three development-stage biotic technologies (plant virus-based nanoparticle (VIN), elastin-like polypeptide (ELP), and oilbody-oleosin (OLE)). McNulty et al. also compared chemical and biological pharmaceutical production for human life support in space. Chemical pharmaceutical synthesis requires reaction-specific inputs, complex synthesis steps, the use of organic solvents, and generates substantial waste. Recent advances in biotechnology offers promise for biological pharmaceutical production as a means to address low occurrence, high impact health hazards (e.g., sepsis, ear infection, glaucoma)¹²⁹.

Conclusion:

The risk of ineffective or toxic medications during long-duration exploration spaceflight is elevated for a Mars planetary mission. The challenge remains to assemble a comprehensive and robust formulary to address anticipated medical needs, that can remain stable, safe, and effective for the duration of an exploration mission, and—when accompanied by pharmaceutical stability assessment techniques—to verify purity and efficacy in a non-destructive, remote environment. Storage and packaging solutions are also warranted to optimize shelf life, purity, and quality. This literature review provides a compilation of research efforts currently underway offering innovative risk mitigation strategies and countermeasures aimed at providing safe and efficacious pharmaceutical care for exploration spaceflight.

Dedication:

This article is dedicated to the memory of NASA scientist Dr. Lakshmi Putcha who blazed a trail of research and innovation and whose contributions continue to inspire Pharmaceutical Scientists to reach for the stars.

Trade names and trademarks are used in this report for identification only. Their usage does not constitute an official endorsement, either expressed or implied, by the National Aeronautics and Space Administration.

References:

1. Billica, R. 2000. In-flight Medical Events for US Astronauts During Space Shuttle Program STS-1 through STS-89, April 1981–January 1998. Presentation to the Institute of Medicine Committee on Creating a Vision for Space Medicine During Travel Beyond Earth Orbit, February 22, Johnson Space Center, Houston.
2. Institute of Medicine, Technical Report, Committee on Creating a Vision for Space Medicine during Travel beyond Earth Orbit, February 22, 2001, Johnson Space Center, Houston.
3. Institute of Medicine, Technical Report, Committee on Ethics Principles and Guidelines for Health Standards for Long Duration and Exploration Spaceflights, 2014
4. Hazards of Human Spaceflight, NAT'L AERONAUTICS & SPACE ADMIN. NASA, 2019a. Five Hazards of Human Spaceflight <https://www.nasa.gov/hrp/hazards> (last accessed 08 Feb 2023).
5. Antonsen, E. Human System Risk Management Plan, JSC-66705 Rev. A. (2020)
6. Erik L. Antonsen & Rebekah D. Reed, Policy Considerations for Precision Medicine in Human Spaceflight, 19 Hous. J. HEALTH L. & POL'y 1 (2019)
7. Antonsen, E., Hansen, A., Shah, R., Reed, R. & Canga, M. Conceptual Drivers for an Exploration Medical System. In 67th International Astronautical Congress vol. IAC-16,A1,3,9,x35689 10 (International Astronautical Federation, 2016).
8. Blue RS, Bayuse TM, Daniels VR, Wotring VE, Suresh R, Mulcahy RA, Antonsen EL. Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding. npj Microgravity 5, 14 (2019). <https://doi.org/10.1038/s41526-019-0075-2>.
9. Blue RS, Chancellor JC, Antonsen EL, Bayuse TM, Daniels VR, Wotring VE. Limitations in predicting radiation-induced pharmaceutical instability during long-duration spaceflight. npj Microgravity 5, 15 (2019). <https://doi.org/10.1038/s41526-019-0076-1>
10. Antonsen EL, Myers JG, Boley L, Arellano J, Kerstman E, Kadwa B, Buckland DM, Van Baalen M. Estimating medical risk in human spaceflight. NPJ Microgravity (2022). Mar 31;8(1):8. PMID: 35361776; PMCID: PMC8971481. <https://doi.org/10.1038/s41526-022-00193-9>
11. Ginsburg, G. S., & Phillips, K. A. (2018). Precision Medicine: From Science To Value. Health affairs (Project Hope), 37(5), 694–701. <https://doi.org/10.1377/hlthaff.2017.1624>
12. Doarn CR, Polk J D, Shepanek M. Health challenges including behavioral problems in long-duration spaceflight. Neurol India 2019;67:190-195
13. Stingl JC, Welker S, Hartmann G, Damann V, Gerzer R (2015) Where Failure Is Not an Option – Personalized Medicine in Astronauts. PLoS ONE 10(10): e0140764. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140764>
14. Walton, M. E. & Kerstman, E. L. Quantification of medical risk on the international space station using the integrated medical model. Aerosp. Med Hum. Perform. 91, 332–342 (2020).
15. Hoa Q. Nguyen, Stephen D. Stamatis, Lee E. Kirsch, A Novel Method for Assessing Drug Degradation Product Safety Using Physiologically-Based Pharmacokinetic Models and Stochastic Risk Assessment, Journal of Pharmaceutical Sciences, Volume 104, Issue 9, 2015, Pages 3101-3119, ISSN 0022-3549, <https://doi.org/10.1002/jps.24452>.

16. Deepika D, Kumar V. The Role of “Physiologically Based Pharmacokinetic Model (PBPK)” New Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk Assessment. *International Journal of Environmental Research and Public Health*. 2023; 20(4):3473. <https://doi.org/10.3390/ijerph20043473>
17. Koromina M, Pandi MT, Patrinos GP. Rethinking Drug Repositioning and Development with Artificial Intelligence, Machine Learning, and Omics. *OMICS*. 2019 Nov;23(11):539-548. <https://doi.org/10.1089/omi.2019.0151>. Epub 2019 Oct 25. PMID: 31651216.
18. DiCarlo, A.L., Cassatta, D.R., Dowling, W.E., Esker, J.L., Hewitt, J.A., Selivanovac, O., Williams, M.S., , Price, P.W., 2018. Challenges and Benefits of Repurposing Products for Use during a Radiation Public Health Emergency Lessons Learned from Biological Threats and other Disease Treatments. *Radiat. Res.* 190 (6), 659–676. <https://doi.org/10.1667/RR15137.1>.
19. Food and Drug Administration, HHS. (2016). Abbreviated New Drug Applications and 505 (b)(2) Applications. Final rule. Federal register, 81(194), 69580-69658.
20. P.B. Madrid, P.Y. Chang, Accelerating space radiation countermeasure development through drug repurposing, *Life Sciences in Space Research*, Volume 35, 2022, Pages 30-35, ISSN 2214-5524, <https://doi.org/10.1016/j.lssr.2022.07.002>.
21. Manian V, Orozco-Sandoval J and Diaz-Martinez V (2021) An Integrative Network Science and Artificial Intelligence Drug Repurposing Approach for Muscle Atrophy in Spaceflight Microgravity. *Front. Cell Dev. Biol.* 9:732370. <https://doi.org/10.3389/fcell.2021.732370>
22. Manian, V.; Orozco-Sandoval, J.; Diaz-Martinez, V.; Janwa, H.; Agrinoni, C. Detection of Target Genes for Drug Repurposing to Treat Skeletal Muscle Atrophy in Mice Flown in Spaceflight. *Genes* 2022, 13, 473. <https://doi.org/10.3390/genes13030473>
23. Lu, C., Liu, S., Shi, W. et al. Systemic evolutionary chemical space exploration for drug discovery. *J Cheminform* 14, 19 (2022). <https://doi.org/10.1186/s13321-022-00598-4>
24. Iria Seoane-Viaño, Jun Jie Ong, Abdul W. Basit, Alvaro Goyanes, To infinity and beyond: Strategies for fabricating medicines in outer space, *International Journal of Pharmaceutics: X*, Volume 4, 2022, 100121, ISSN 2590-1567, <https://doi.org/10.1016/j.ijpx.2022.100121>
25. Arnold, C., 2019. Who Shrank the Drug Factory? Briefcase-Sized Labs Could Transform Medicine [Internet]. Available from: <https://www.nature.com/articles/d41586-019-03455-x> (last accessed 30 May 2020).
26. Steiner, S., Wolf, J., Glatzel, S., Andreou, A., Granda, J.M., Keenan, G., Hinkley, T., Aragon-Camarasa, G., Kitson, P.J., Angelone, D., Cronin, L., 2019. Organic synthesis in a modular robotic system driven by a chemical programming language. *Science* 363, eaav2211.
27. University of Glasgow, 2018. ‘Chemputer’ Promises App-Controlled Revolution for Drug Production [Internet]. Available from: <https://phys.org/news/2018-11-chemputer-app-controlled-revolution-drug-production.html> (last accessed 02/13/23)
28. Wood, C., 2020. Scientists Make Digital Breakthrough in Chemistry that Could Revolutionize the Drug Industry [Internet]. Available from: <https://www.cnbc.com/2020/10/24/how-a-digital-breakthrough-could-revolutionize-drug-industry.html> (last accessed 02/13/2023)
29. McClure-Begley, T., n.d. Battlefield Medicine, Defense Advanced Research Projects Agency. [Internet]. Available from: <https://www.darpa.mil/program/battlefield-medicine#> (last accessed 02/13/2023)

30. Adiga, R., Al-adhami, M., Andar, A., Borhani, S., Brown, S., Burgenson, D., Cooper, M.A. Deldari, S., Frey, D.D., Ge, X., Guo, H., Gurramkonda, C., Jensen, P., Kostov, Y., LaCourse, W., Liu, Y., Moreira, A., Mupparapu, K., Peñalber-Johnstone, C., Pilli, M., Punshon-Smith, B., Rao, A., Rao, G., Rauniyar, P., Snovida, S., Taurani, K., Tilahun, D., Tolosa, L., Tolosa, M., Tran, K., Vattam, K., Veeraraghavan, S., Wagner, B., Wilhide, J., Wood, D.W., Zuber, A., 2018. Point-of-care production of therapeutic proteins of good-manufacturing-practice quality. *Nat. Biomed. Eng.* 2, 675–686.
31. El Karoui M, Hoyos-Flight M, Fletcher L. Future Trends in Synthetic Biology-A Report. *Front Bioeng Biotechnol.* 2019 Aug 7;7:175. <https://doi.org/10.3389/fbioe.2019.00175> . PMID: 31448268; PMCID: PMC6692427.
32. Trosset JY, Carbonell P. Synthetic biology for pharmaceutical drug discovery. *Drug Des Devel Ther.* 2015 Dec 3;9:6285-302. <https://doi.org/10.2147/DDDT.S58049>. PMID: 26673570; PMCID: PMC4675648.
33. Bendicho-Lavilla C, Seoane-Viaño I, Otero-Espinar FJ, Luzardo-Álvarez A. Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics. *Acta Pharm Sin B.* 2022 Feb;12(2):621-636. <https://doi.org/10.1016/j.apsb.2021.08.003> . Epub 2021 Aug 10. PMID: 35256935; PMCID: PMC8897023.
34. Brooks, S.M., Alper, H.S. Applications, challenges, and needs for employing synthetic biology beyond the lab. *Nat Commun* 12, 1390 (2021). <https://doi.org/10.1038/s41467-021-21740-0>
35. Pflueger-Peters, N., 2020. Karen McDonald Receives TRISH Grant to Study Just-in-Time Medications for Space Exploration, UCDAVIS [Internet]. Available from: <https://che.engineering.ucdavis.edu/news/karen-mcdonald-receives-trish-grant-study-just-time-medications-space-exploration> (last accessed 08 Mar 2023).
36. American Association for the Advancement of Science (AAAS), Reports and Proceedings, CS, 2022. Space-Grown Lettuce Could Help Astronauts Avoid Bone Loss [Internet]. Available from: <https://www.eurekalert.org/news-releases/945812> (last accessed 08 Mar 2023).
37. Turrone, S., Magnani, M., Kc, P., Lesnik, P., Vidal, H., & Heer, M. (2020). Gut microbiome and space travelers' health: state of the art and possible pro/prebiotic strategies for long-term space missions. *Frontiers in physiology*, 11, 553929.
38. Cao, W., McCallum, N. C., Ni, Q. Z., Li, W., Boyce, H., Mao, H., Sun, H., Thompson, M., Battistella, C., Wasielewski, M., Dhinojwala, A., Shawkey, M., Burkart, M., Wang, Z., Gianneschi, N. C. (2020). Selenomelanin: An Abiotic Selenium Analogue of Pheomelanin. *Journal of the American Chemical Society*, 142(29), 12802-12810. <https://doi.org/10.1021/jacs.0c05573>
39. Westover, C., Najjar, D., Meydan, C., Grigorev, K., Veling, M. T., Iosim, S., ... & Chang, R. L. (2020). Engineering Radioprotective Human Cells Using the Tardigrade Damage Suppressor Protein, DSUP 2. *spaceflight*, 50, 51
40. Simon, Á.; Smarandache, A.; Iancu, V.; Pascu, M.L. Stability of Antimicrobial Drug Molecules in Different Gravitational and Radiation Conditions in View of Applications during Outer Space Missions. *Molecules* 2021, 26, 2221. <https://doi.org/10.3390/molecules26082221>
41. Smarandache A, Simon A, Tozar T, Nastasa V, Pascu ML. Stability studies on Promethazine unexposed and exposed to UV laser radiation. Vol 9549: SPIE; 2015 <https://doi.org/10.1117/12.2189289>
42. Du B, Daniels VR, Vaksman Z, Boyd JL, Crady C, Putcha L. Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. *AAPS J.* 13, 299–308 (2011).
43. Mehta, P.J., Bhayani, D. (2022). Physicochemical Stability of Space Medicines. In: Pathak, Y.V., Araújo dos Santos, M., Zea, L. (eds) *Handbook of Space Pharmaceuticals*. Springer, Cham. https://doi.org/10.1007/978-3-030-05526-4_35

44. Daniels, NASA Technical Report, Document ID: 20210022084, Conference Paper, ExMC GROUND-BASED SPACE RADIATION ANALOG PILOT DRUG STABILITY STUDY: FINAL DATA REVIEW. September 28, 2021, Presented: Human Research Program (HRP) Investigators' Workshop (IWS) 2022
45. Zwart, S., Kloeris, V., Perchonok, M., Braby, L. & Smith, S. Assessment of nutrient stability in foods from the space food system after long-duration spaceflight on the ISS. *J. Food Sci.* 74, H209–H217 (2009).
46. Chuong, M., Prasad, D., Leduc, B., Du, B. & Putcha, L. Stability of vitamin B complex in multivitamin and multimineral supplement tablets after space flight. *J. Pharm. Biomed. Anal.* 55, 1197–1200 (2011).
47. Wotring, V. Chemical potency and degradation products of medications stored over 550 earth days at the international space station. *AAPS J.* 18, 210–216 (2016).
48. Wu, L. & Chow, D. Degradation Analysis of Medications from ISS Using LC-MS/MS Assays: NSBRI RFA 15-01 First Award Fellowship, Final Report. Tech. Rep., National Space Biomedical Research Institute (2016).
49. Cory, W., James, V., Lamas, A., Mangiaracina, K. & Moon, J. Analysis of Degradation of Pharmaceuticals Stored on the International Space Station. Tech. Rep. 17091, Proceedings of the NASA Human Research Program Investigator Workshop (2017).
50. Daniels, V. & Bayuse, T. Risk of ineffective or toxic medications during long-duration exploration spaceflight. Oral Presentation, NASA Human Systems Risk Board (2018). Daniels, V., Bayuse, T., Mulcahy, R., McGuire, K. & Antonsen, E. in *The Pathway to a Safe and Effective Medication Formulary for Exploration Spaceflight*. Tech. Report No. 13658. Proceedings of the NASA Human Research Program Investigator Workshop (2017).
51. WHO Stability Guideline, Annex 10, Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products, WHO Technical Report Series, No. 1010, 2018 ICH, 2018. https://extranet.who.int/pqweb/sites/default/files/documents/TRS1010_Annex10.pdf (last accessed 03/20/23)
52. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Q1A (R2), Stability Testing of New Pharmaceutical Products (Geneva, Switzerland, 2003).
53. Yoshioka S, Stella VJ, *Stability of Drugs and Dosage Forms*. Boston, MA: Springer US; 2002:3-137. Kluwer Academic Publishers, New York, pp 139–150. <https://doi.org/10.1007/b114443>
54. Bhangare, D., Rajput, N., Jadav, T. et al. Systematic strategies for degradation kinetic study of pharmaceuticals: an issue of utmost importance concerning current stability analysis practices. *J Anal Sci Technol* 13, 7 (2022). <https://doi.org/10.1186/s40543-022-00317-6>
55. Fathima, Nushruth & Tirunagari, Mamatha & Qureshi, H.K. & Nandagopal, Anitha & Rao, J.. (2011). Drug-exciptient interaction and its importance in dosage form development. *Journal of Applied Pharmaceutical Science*. 1. 66-71.
56. Dong M, Huynh-Ba K. Stability Studies and Testing of Pharmaceuticals-An Overview. *LCGC North America*. 2020;38(6):325–336.
57. Kashvi C. Shah, Maitri B. Shah, Sakshi J. Solanki, Vikas D. Makwana, Dipen K. Sureja, Anuradha K. Gajjar, Kunjan B. Bodiwala, Tejas M. Dhameliya, Recent advancements and applications of Raman spectroscopy in pharmaceutical analysis, *Journal of Molecular Structure*, Volume 1278, 2023, 134914, ISSN 0022-2860, <https://doi.org/10.1016/j.molstruc.2023.134914>.

58. Chen, H., Lin, Z., and Tan, C. (2018). Nondestructive discrimination of pharmaceutical preparations using near-infrared spectroscopy and partial least-squares discriminant analysis. *Anal. Lett.* 51, 564–574. <https://doi.org/10.1080/00032719.2017.1339070>
59. Rodionova, O. Y., Balyklova, K. S., Titova, A. V., and Pomerantsev, A. L. (2018). Application of NIR spectroscopy and chemometrics for revealing of the 'high quality fakes' among the medicines. *Forensic Chem.* 8, 82–89. <https://doi.org/10.1016/j.forc.2018.02.004>
60. Carruthers H, Clark D, Clarke F, Faulds K, Graham D. Comparison of Raman and Near-Infrared Chemical Mapping for the Analysis of Pharmaceutical Tablets. *Applied Spectroscopy*. 2021;75(2):178-188. <https://doi.org/10.1177/0003702820952440>
61. A. Silge, K. Weber, D. Cialla-May, L. Müller-Böttcher, D. Fischer, J. Popp, Trends in pharmaceutical analysis and quality control by modern Raman spectroscopic techniques, *TrAC Trends Anal. Chem.* 153 (2022) 116623.
62. Biba, E., & Pappa, H. (2023). Spectroscopy and Spectroscopic Analytical Techniques in the United States Pharmacopeia–National Formulary (USP–NF). 38(S3), 5–8.
63. Bērziņš, K., Fraser-Miller, S.J., Gordon, K.C. Pseudo-3D Subsurface Imaging of Pharmaceutical Solid Dosage Forms Using Micro-spatially Offset Low-Frequency Raman Spectroscopy. *Analytical Chemistry* 2021 93 (25), 8986-8993, <https://doi.org/10.1021/acs.analchem.1c167010>
64. Alaa A. Makki, Franck Bonnier, Renaud Respaud, Fatma Chtara, Ali Tfayli, Clovis Tauber, Dominique Bertrand, Hugh J. Byrne, Elhadi Mohammed, Igor Chourpa, Qualitative and quantitative analysis of therapeutic solutions using Raman and infrared spectroscopy, *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, Volume 218, 2019, Pages 97-108, ISSN 1386-1425, <https://doi.org/10.1016/j.saa.2019.03.056>.
65. M.A. Sultan, M.M. Abou El-Alamin, A.W. Wark, M.M. Azab, Detection and quantification of warfarin in pharmaceutical dosage form and in spiked human plasma using surface enhanced Raman scattering, *Spectrochim. Acta -Part A Mol. Biomol. Spectrosc.* 228 (2020) 117533.
66. C. Liu, X. Xu, C. Wang, G. Qiu, W. Ye, Y. Li, D. Wang, ZnO/Ag nanorods as a prominent SERS substrate contributed by synergistic charge transfer effect for simultaneous detection of oral antidiabetic drugs pioglitazone and phenformin, *Sens. Actuat. B Chem.* 307 (2020) 127634.
67. E.M. da Silva, G.C. de Oliveira, A.B. de Siqueira, A.J. Terezo, M. Castilho, Development of a composite electrode based on graphite and polycaprolactone for the determination of antihypertensive drugs, *Microchem. J.* 158 (2020) 105228.
68. Z. Wang, Y. Peng, C. Shi, L. Wang, X. Chen, W. Wu, X. Wu, Y. Zhu, J. Zhang, G. Cheng, S. Zhuang, Qualitative and quantitative recognition of chiral drugs based on terahertz spectroscopy, *Analyst* 146 (2021) 3888–3898.
69. J. Zini, J. Kekkonen, V.A. Kaikkonen, T. Laaksonen, P. Keränen, T. Talala, A.J. Mäkinen, M. Yliperttula, I. Nissinen, Drug diffusivities in nanofibrillar cellulose hydrogel by combined time-resolved Raman and fluorescence spectroscopy, *J. Control. Release.* 334 (2021) 367–375.
70. G. Sarp, E. Yilmaz, g-C₃N₄@TiO₂@Fe₃O₄ multifunctional nanomaterial for magnetic solid-phase extraction and photocatalytic degradation-based removal of trimethoprim and isoniazid, *ACS Omega* 7 (2022) 23223–23233.

71. Sara Fateixa, Otílio Mulandeza, Helena I.S. Nogueira, Tito Trindade, Raman imaging studies on the stability of Paracetamol tablets under different storage conditions, *Vibrational Spectroscopy*, Volume 124, 2023, 103488, ISSN 0924-2031, <https://doi.org/10.1016/j.vibspec.2022.103488>
72. N. Wang, H. Cao, L. Wang, F. Ren, Q. Zeng, X. Xu, J. Liang, Y. Zhan, X. Chen, Recent advances in spontaneous raman spectroscopic imaging: instrumentation and applications, *Curr. Med Chem.* 27 (2019) 6188–6207, <https://doi.org/10.2174/0929867326666190619114431>.
73. A. Rzhetskii, The recent advances in raman microscopy and imaging techniques for biosensors, *Biosens. (Basel)* 9 (2019), <https://doi.org/10.3390/bios9010025>.
74. T. Ľapkov´a, T. Pek´arek, B. Hanulíkov´a, P. Matějka, Application of reverse engineering in the field of pharmaceutical tablets using Raman mapping and chemometrics, *J. Pharm. Biomed. Anal.* 209 (2022), 114496, <https://doi.org/10.1016/j.jpba.2021.114496>.
75. Dorián László Galata, Boldizsár Zsiros, Lilla Alexandra Mészáros, Brigitta Nagy, Edina Szabó, Attila Farkas, Zsombor Kristóf Nagy, Raman mapping-based non-destructive dissolution prediction of sustained-release tablets, *Journal of Pharmaceutical and Biomedical Analysis*, Volume 212, 2022, 114661, ISSN 0731-7085, <https://doi.org/10.1016/j.jpba.2022.114661>
76. Lanzarotta A, Kern S, Batson J, Boyd B, Kimani MM, Kuo W, LaGarde D, Loh M, Adeosun LL, Lorenz L, Melendez R, Morales-Garcia F, Thatcher M, Wetherby AE Jr, Witkowski MR. Rapid detection of active pharmaceutical ingredients in drug products collected at an international mail facility by a satellite laboratory using a "toolkit" consisting of a handheld Raman spectrometer, portable mass spectrometer and portable FT-IR spectrometer. *J Pharm Biomed Anal.* 2023 Feb 5;224:115153. Epub 2022 Nov 16. PMID: 36423496. <https://doi.org/10.1016/j.jpba.2022.115153>
77. International Conference on harmonization of technical requirements for registration of pharmaceuticals for human use, ICH harmonized tripartite guideline. 2003. Evaluation for Stability Q1E.
78. International Conference on harmonization of technical requirements for registration of pharmaceuticals for human use, ICH harmonized tripartite guideline. 2009. Pharmaceutical Development Q8(R2).
79. McCurdy, V. (2011) *Quality by Design, in Process Understanding: For Scale-Up and Manufacture of Active Ingredients*, First Edition. Edited by Ian Houson. 2011 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2011 by Wiley-VCH Verlag GmbH & Co. KGaA
80. Qiu, F. Accelerated Predictive Stability: An introduction. In *Accelerated Predictive Stability (APS) Fundamentals and Pharmaceutical Industry Practices*; Academic Press: Cambridge, MA, USA, 2018; pp. 3–14. ISBN 9780128027868, <https://doi.org/10.1016/B978-0-12-802786-8.00001-2>.
81. Williams, H. (2018). Predictive Stability Testing Utilizing Accelerated Stability Assessment Program (ASAP) Studies. In: Bajaj, S., Singh, S. (eds) *Methods for Stability Testing of Pharmaceuticals. Methods in Pharmacology and Toxicology*. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7686-7_10
82. Waterman K. C. (2011). The application of the Accelerated Stability Assessment Program (ASAP) to quality by design (QbD) for drug product stability. *AAPS PharmSciTech*, 12(3), 932–937. <https://doi.org/10.1208/s12249-011-9657-3>
83. González-González, O.; Ramirez, I.O.; Ramirez, B.I.; O'Connell, P.; Ballesteros, M.P.; Torrado, J.J.; Serrano, D.R. Drug Stability: ICH versus Accelerated Predictive Stability Studies. *Pharmaceutics* 2022, 14, 2324. <https://doi.org/10.3390/pharmaceutics14112324>

84. Merienne, Camille, Marchand, Chloe, Filali, Samira, Salmon, Damien, Pivot, Christine and Pirot, Fabrice. "Measurement, analysis and prediction of amoxicillin oral dose stability from integrated molecular description approach and accelerated predictive stability (APS)" *Pharmaceutical Technology in Hospital Pharmacy*, vol. 5, no. 1, 2020, pp. 20200009. <https://doi.org/10.1515/pthp-2020-0009>
85. Furness, M.S., Cai, H., Chandramouli, S. et al. Modeling Approaches to Reimagine Stability (MARS) for Enabling Earlier Access to Critical Drugs for Patients with Unmet Medical Needs. *AAPS PharmSciTech* **24**, 35 (2023). <https://doi.org/10.1208/s12249-022-02498-0>
86. Mandal, P., Khanam, J., Karmakar, S. et al. An Audit on Design of Pharmaceutical Packaging. *J Package Technol Res* **6**, 167–185 (2022). <https://doi.org/10.1007/s41783-022-00141-8>
87. Jafarzadeh, S., Nooshkam, M., Zargar, M. et al. Green synthesis of nanomaterials for smart biopolymer packaging: challenges and outlooks. *J Nanostruct Chem* (2023). <https://doi.org/10.1007/s40097-023-00527-3>
88. Rukmanikrishnan, B., Ismail, F.R.M., Manoharan, R.K., Kim, S. S., Lee, J.: Blends of gellan gum/xanthan gum/zinc oxide based nanocomposites for packaging application: rheological and anti-microbial properties. *Int. J. Biol. Macromol.* **148**, 1182–1189 (2020)
89. Patil, A.S., Waghmare, R.D., Pawar, S.P., Salunkhe, S.T., Kolekar, G.B., Sohn, D., Gore, A.H.: Photophysical insights of highly transparent, flexible and re-emissive PVA@ WTR-CDs composite thin films: a next generation food packaging material for UV blocking applications. *J. Photochem. Photobiol. A.* **400**, 112647 (2020)
90. Razali, M.H., Ismail, N.A., Amin, K.A.M.: Titanium dioxide nanotubes incorporated gellan gum bio-nanocomposite film for wound healing: effect of TiO₂ nanotubes concentration. *Int. J. Biol. Macromol.* **153**, 1117–1135 (2020)
91. Rhim, J.-W., Ng, P.K.W.: Natural biopolymer-based nanocomposite films for packaging applications. *Crit. Rev. Food Sci. Nutr.* **47**, 411–433 (2007)
92. Tang, H., Xiong, H., Tang, S., Zou, P.: A starch-based biodegradable film modified by nano silicon dioxide. *J. Appl. Polym. Sci.* **113**, 34–40 (2009)
93. Arpita Chakravarti, K. Gowthamarajan, Jayakumar Venkatesan, 2022. A brief introduction to the universe of space medication. *J. Med. P'ceutical Allied Sci.* **V 11 - I 1**, Pages - 4770 - 4776 <https://doi:10.55522/jmpas.V11I2.2946>
94. Daniela Iguchi, Seishi Ohashi, Ghizelle J. E. Abarro, Xianze Yin, Scott Winroth, Chris Scott, Molly Gleydura, Lin Jin, Nithya Kanagasagar, Cherie Lo, Carlos Rodriguez Arza, Pablo Froimowicz, and Hatsuo Ishida *ACS Omega* **2018** *3* (9), 11569-11581 <https://DOI.org/10.1021/acsomega.8b01297>
95. Naito, M., Kodaira, S., Ogawara, R., Tobita, K., Someya, Y., Kusumoto, T., Kusano, H., Kitamura, H., Koike, M., Uchihori, Y., Yamanaka, M., Mikoshiba, R., Endo, T., Kiyono, N., Hagiwara, Y., Kodama, H., Matsuo, S., Takami, Y., Sato, T., & Orimo, S. I. (2020). Investigation of shielding material properties for effective space radiation protection. *Life sciences in space research*, Volume 26, 2020, Pages 69-76, ISSN 2214-5524, <https://doi.org/10.1016/j.lssr.2020.05.001>
96. Jeffrey R. Vieregg, Steven J. Martin, Adam P. Breeland, Christopher M. Weikart and Matthew V. Tirrell *PDA Journal of Pharmaceutical Science and Technology* January 2018, **72** (1) 35-43; DOI: <https://doi.org/10.5731/pdaipst.2017.008011>
97. Mehta P, Bhayani D (2017) Impact of space environment on stability of medicines: challenges and prospects. *J Pharm Biomed Anal* **136**:111–119. <https://doi.org/10.1016/j.jpba.2016.12.040>

98. Kfoury M, Sahraoui AL-H, Bourdon N, Laruelle F, Fontaine J, Auezova L, Greige-gerges H Fourmentin S (2016) Solubility, photostability and antifungal activity of phenylpropanoids encapsulated in cyclodextrins. *Food Chem* 196:518–525. <https://doi.org/10.1016/j.foodchem.2015.09.078>
99. Lai F, Pireddu R, Corrias F, Maria A, Valenti D, Pini E, Sinico C (2013) Nanosuspension improves tretinoin photostability and delivery to the skin. *Int J Pharm* 458:104–109. <https://doi.org/10.1016/j.ijpharm.2013.10.007>
100. Aubert Maquille, Jean-Louis Habib Jiwani, Bernard Tilquin, Radiosterilization of drugs in aqueous solutions may be achieved by the use of radioprotective excipients, *International Journal of Pharmaceutics*, Volume 349, Issues 1–2, 2008, Pages 74–82, ISSN 0378-5173, <https://doi.org/10.1016/j.ijpharm.2007.07.024>
101. Guo, J., Zhao, Z., Shang, Z.-F., Tang, Z., Zhu, H., & Zhang, K. (2023). Nanodrugs with intrinsic radioprotective exertion: Turning the double-edged sword into a single-edged knife. *Exploration*, 3(2), 20220119. <https://doi.org/10.1002/EXP.20220119>
102. Adhikari, M., & Arora, R. (2015). Nano-silymarin provides protection against γ -radiation-induced oxidative stress in cultured human embryonic kidney cells. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, 792, 1–11.
103. Dai C, He L, Ma B, Chen T. Facile Nanolization Strategy for Therapeutic Ganoderma Lucidum Spore Oil to Achieve Enhanced Protection against Radiation-Induced Heart Disease. *Small*. 2019 Sep;15(36) e1902642. PMID: 31353836. <https://doi:10.1002/sml.201902642>
104. Irina Pereira, Carina Monteiro, Miguel Pereira-Silva, Diana Peixoto, Cláudia Nunes, Salette Reis, Francisco Veiga, Michael R. Hamblin, Ana Cláudia Paiva-Santos, Nanodelivery systems for cutaneous melanoma treatment, *European Journal of Pharmaceutics and Biopharmaceutics*, Volume 184, 2023, Pages 214–247, ISSN 0939-6411, <https://doi.org/10.1016/j.ejpb.2023.02.002>
105. Qingliang Yang 1,2, Feng Yuan 1, Lei Xu 1, Qinying Yan 1,2, Yan Yang 1,2, Danjun Wu 1,2, Fangyuan Guo 1,2 and Gensheng Yang 1,2,* An Update of Moisture Barrier Coating for Drug Delivery. *Pharmaceutics* 2019, 11, 436; <https://doi:10.3390/pharmaceutics11090436>
106. Rolley, N., Bonnin, M., Lefebvre, G., Verron, S., Bargiel, S., Robert, L., . . . Calvignac, B. (2021). Galenic Lab-on-a-Chip concept for lipid nanocapsules production. *Nanoscale*, 13(27), 11899–11912. <https://doi:10.1039/D1NR00879J>
107. Salawi, A. Pharmaceutical Coating and Its Different Approaches, a Review. *Polymers* 2022, 14, 3318. <https://doi.org/10.3390/polym14163318>
108. Tekade, R.K.; Maheshwari, R.; Tekade, M. *Biopolymer-Based Nanocomposites for Transdermal Drug Delivery*. Biopolymer-Based Composites; Elsevier: Amsterdam, The Netherlands, 2017; pp. 81–106.
109. Grenier, P.; Taillemite, J.; Serreau, S.; Nhamias, A. Pharmaceutical Composition Containing Coated, Floating Particles. US Patent US8927028B2, 6 January 2015.
110. Chen, W.; Wang, J.; Desai, D.; Chang, S.Y.; Kiang, S.; Lyngberg, O. A Strategy for Tablet Active Film Coating Formulation Development Using a Content Uniformity Model and Quality by Design Principles. In *Comprehensive Quality by Design for Pharmaceutical Product Development and Manufacture*; Reklaitis, G.V., Seymour, C., García-Munoz, S., Eds.; Chemical Engineering Progress: New York, NY, USA, 2017; pp. 193–233.
111. Moon, C.; Oh, E. Rationale and strategies for formulation development of oral fixed dose combination drug products. *J. Pharm. Investig.* 2016, 46, 615–631.

112. Ng, L.H.; Ling, J.K.U.; Hadinoto, K. Formulation Strategies to Improve the Stability and Handling of Oral Solid Dosage Forms of Highly Hygroscopic Pharmaceuticals and Nutraceuticals. *Pharmaceutics* 2022, 14, 2015. <https://doi.org/10.3390/pharmaceutics14102015>
113. Zheng, X.; Wu, F.; Hong, Y.; Shen, L.; Lin, X.; Feng, Y. Improvements in sticking, hygroscopicity, and compactibility of effervescent systems by fluid-bed coating. *RSC Adv.* 2019, 9, 31594–31608
114. Ajmal Zarinwall, Viktor Maurer, Jennifer Pierick, Victor Marcus Oldhues, Julian Cedric Porsiel, Jan Henrik Finke & Georg Garnweitner (2022) Amorphization and modified release of ibuprofen by post-synthetic and solvent-free loading into tailored silica aerogels, *Drug Delivery*, 29:1, 2086-2099, <https://DOI:10.1080/10717544.2022.2092237>
115. Binh M. Trinh, Boon P. Chang, Tizazu H. Mekonnen, The barrier properties of sustainable multiphase and multicomponent packaging materials: A review, *Progress in Materials Science*, Volume 133, 2023, 101071, ISSN 0079-6425, <https://doi.org/10.1016/j.pmatsci.2023.101071>.
116. Samantaray PK, Little A, Haddleton DM, McNally T, Tan B, Sun Z, et al. Poly(glycolic acid) (PGA): a versatile building block expanding high performance and sustainable bioplastic applications. *Green Chem* 2020;22(13):4055–81.
117. Ogunsona EO, Mekonnen TH. Multilayer assemblies of cellulose nanocrystal – Polyvinyl alcohol films with robust physical integrity and multi-functional properties. *J Colloid Interface Sci* 2020;580:56–67. <https://doi.org/10.1016/j.jcis.2020.07.012>
118. Liu H, Wu J, Liu C, Pan B, Kim NH, Lee JH. Differently-charged graphene-based multilayer films by a layer-by-layer approach for oxygen gas barrier application. *Compos Part B Eng* 2018;155:391–6. <https://doi.org/10.1016/J.COMPOSITESB.2018.08.137>.
119. Lange J, Wyser Y. Recent innovations in barrier technologies for plastic packaging—a review. *Packag Technol Sci* 2003;16:149–58. <https://doi.org/10.1002/PTS.621>
120. Bayer IS. Zein in Food Packaging. *Sustain Food Packag Technol* 2021:199–224. <https://doi.org/10.1002/9783527820078.CH7>
121. Dou Y, Zhang L, Zhang B, He M, Shi W, Yang S, et al. Preparation and Characterization of Edible Dialdehyde Carboxymethyl Cellulose Crosslinked Feather Keratin Films for Food Packaging. *Polymers* 2020;12(1):158.
122. Vicente AA, Cerqueira MA, Hilliou L, Rocha CMR. Protein-based resins for food packaging. *Multifunct Nanoreinforced Polym Food Packag* 2011:610–48. <https://doi.org/10.1533/9780857092786.4.610>
123. Kasaai MR. Zein and zein -based nano-materials for food and nutrition applications: A review. *Trends Food Sci Technol* 2018;79:184–97. <https://doi.org/10.1016/J.TIFS.2018.07.015>
124. Fabra MJ, Lopez-Rubio A, Lagaron JM. High barrier polyhydroxyalcanoate food packaging film by means of nanostructured electrospun interlayers of zein. *Food Hydrocoll* 2013;32:106–14. <https://doi.org/10.1016/J.FOODHYD.2012.12.007>
125. Chilakamarthy CR, Mahmood S, Saffe SNBM, Arifin MA Bin, Gupta A, Sikkandar MY, et al. Extraction and application of keratin from natural resources: a review. *3 Biotech* 2021;11:1–12. <https://doi.org/10.1007/S13205-021-02734-7/FIGURES/7>
126. Chen X, Wu S, Yi M, Ge J, Yin G, Li X. Preparation and Physicochemical Properties of Blend Films of Feather Keratin and Poly(vinyl alcohol) Compatibilized by Tris(hydroxymethyl)aminomethane. *Polymers* 2018;10(10):1054.

127. Alashwal BY, Saad Bala M, Gupta A, Sharma S, Mishra P. Improved properties of keratin-based bioplastic film blended with microcrystalline cellulose: A comparative analysis. J King Saud Univ - Sci 2020;32:853–7. <https://doi.org/10.1016/J.JKSUS.2019.03.006>.

128. McNulty MJ, Berliner AJ, Negulescu PG, McKee L, Hart O, Yates K, Arkin AP, Nandi S and McDonald KA (2021) Evaluating the Cost of Pharmaceutical Purification for a Long-Duration Space Exploration Medical Foundry. Front. Microbiol. 12:700863. <https://doi:10.3389/fmicb.2021.700863>

129. McNulty, M. J., Xiong, Y. M., Yates, K., Karuppanan, K., Hilzinger, J. M., Berliner A. J., et al. (2021). Molecular pharming to support human life on the moon, mars, and beyond. Crit. Rev. Biotechnol. 41, 849–864. <https://doi:10.1080/07388551.2021.1888070>